Pro PG receives S19A approval for TNKASE tenecteplase 50mg powder for solution kit (Canada)

Dear Healthcare Professional,

METALYSE tenecteplase (rch) 50mg powder for injection vial plus prefilled syringe AUST R: 75013 - shortage and alternative supply arrangement

Pro Pharmaceuticals Group (ProPG) advises that due to a shortage of Australian registered METALYSE tenecteplase (rch) 50mg powder for injection vial plus prefilled syringe AUST R: 75013. ProPG has arranged for an alternative product TNKASE tenecteplase 50mg powder for solution kit (Canada). The S19A product is registered and marketed in the Canada and the supply is authorised under an exemption granted by the TGA under Section 19A of the Therapeutic Goods Act, 1989 until 31 January 2024.